CG Oncology, Inc. Common stock (CGON)
Who owns CG Oncology, Inc. Common stock (CGON)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.6% of the shares are freely tradable; institutional investors hold 109.9%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RTW INVESTMENTS, LLC | 7.92 | 6,984,808 | +247.1 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 7.62 | 6,720,389 | +1,347.0 | 03/31/2026 |
| Vanguard Group Inc | 7.41 | 6,539,482 | -0.6 | 12/31/2025 |
| Decheng Capital LLC | 7.22 | 6,371,669 | +0.0 | 03/31/2026 |
| Wellington Management Company LLP | 6.09 | 5,371,232 | -10.5 | 03/31/2026 |
| BlackRock Inc | 5.74 | 5,064,180 | +4.6 | 03/31/2026 |
| FMR Inc | 4.27 | 3,764,844 | -12.4 | 03/31/2026 |
| TCG Crossover Management, LLC | 4.16 | 3,670,206 | +0.0 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 4.14 | 3,652,980 | +6.1 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 3.51 | 3,095,098 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Post Leonard E | Director | Sell | 1,000 | 71.17 | 71,170 |
| 15. Jul 2026 | Post Leonard E | Director | Other | 1,000 | 0.60 | 600 |
| 10. Jul 2026 | Mulay James | Director | Sell | 24,165 | 75.16 | 1,816,241 |
| 10. Jul 2026 | Mulay James | Director | Other | 24,165 | 26.63 | 643,514 |
| 17. Apr 2026 | James Mulay | Director | Sell | 15,600 | 73.01 | 1,138,956 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.